The role of artificial cells in the fight against COVID-19: deliver vaccine, hemoperfusion removes toxic cytokines, nanobiotherapeutics lower free radicals and pCO 2 and replenish blood supply
Source abstract
Abstract
This review concentrates on how artificial cells can contribute to helping patients with COVID-19. Artificial cells have led to mRNA vaccines with more improvements to come. Excessive cytokines in severe COVID-19 can damage organs leading to death. Artificial cell-based collodion macroporous activated charcoal adsorbent can effectively remove middle molecular weight range molecules in patients. A novel hemoperfusion device based on collodion membrane macroporous synthetic resin effectively removes cytokines and recovery in COVID-19 patients. This has been approved as an emergency treatment for COVID-19 in China, Europe, and Canada. A recent nanobiotherapeutic containing haemoglobin and up to six times the concentration of red blood cell enzymes: catalase, superoxide dismutase and carbonic anhydrase. In an animal study, this can effectively lower the damaging increase in free radicals and the removal of increased tissue pCO2. This can also help as blood substitute for the severe and critical problem of COVID-19 pandemic donor blood supply crisis.KEY MESSAGESCOVID-19 and its variants have resulted in major pandemics, severe sicknesses, and deaths around the world. COVID-19 and its variants has only started less than 3 years ago, and it is even more recently that we know more about its mechanisms, requirements, prevention, and treatment. This being the case, this is the first review on the present status and future perspectives of the use of the principle of artificial cells for COVID-19 related to vaccines, treatment, and critical donor blood supply shortage.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: COVID-19 Clinical Research Studies · SARS-CoV-2 and COVID-19 Research · Phagocytosis and Immune Regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Departments of Physiology, Medicine and Biomedical Engineering, Faculty of Medicine and Biomedical Sciences, McGill University
References (65)
Show source-provided references
1. 10.1016/S0140-6736(20)30566-310.1016/S0140-6736(20)30566-3 ↗
2. Chang TMS. Artificial cell evolves into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology, artificial cells. Nanomed Biotechnol. 2019;47(1):997–1013.
3. 10.1126/science.146.3643.52410.1126/science.146.3643.524 ↗
4. Chang TMS. Artificial cells. Springfield (IL): Charles C. Thomas; 1972. Out of print but available for free online viewing/download at www.artcell.mcgill.ca/1972bookcovercr.pdf.
5. 10.1038/nrd165910.1038/nrd1659 ↗
6. 10.1038/nrd163210.1038/nrd1632 ↗
7. Chang TMS. Monograph on “Artificial cells: biotechnology, nanotechnology, blood substitutes, regenerative medicine, bioencapsulation, cell/stem cell therapy”. Singapore: World Scientific Publisher/Imperial College Press; 2007. p. 435. Available for free online viewing at https://www.medicine.mcgill.ca/artcell/2007%20ebook%20artcell%20web.pdf
8. 10.1038/d41586-018-07285-110.1038/d41586-018-07285-1 ↗
9. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
10. 10.1039/C7NR03272B10.1039/C7NR03272B ↗
11. 10.3389/fchem.2021.58011810.3389/fchem.2021.580118 ↗
12. Chang TMS. The one-shot vaccine. In: Heden C-G, editor. Socio-economic and ethical implications of enzyme engineering. Stockholm (Sweden): International Federation of Institutes for Advanced Studies; 1975. p. 17–18.
13. Chang TMS. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J Bioeng. 1976;1:25–32.
14. 10.1182/blood-2006-04-01502410.1182/blood-2006-04-015024 ↗
15. Abuchowski A, Kazo GM, Verhoest CR, Jr., et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys. 1984;7(2):175–186.
16. 10.1016/0022-5193(68)90163-X10.1016/0022-5193(68)90163-X ↗
17. 10.1016/S0022-2836(65)80093-610.1016/S0022-2836(65)80093-6 ↗
18. Gregoriadis G, editor. Drug carriers in biology and medicine. New York: Academic Press, Inc.; 1976.
19. 10.1016/0005-2787(76)90527-X10.1016/0005-2787(76)90527-X ↗
20. 10.1016/j.ymthe.2019.02.01210.1016/j.ymthe.2019.02.012 ↗
21. 10.1038/natrevmats.2017.5610.1038/natrevmats.2017.56 ↗
22. 10.1038/nrd427810.1038/nrd4278 ↗
23. 10.1159/00050703910.1159/000507039 ↗
24. Chang TMS. Semipermeable aqueous microcapsules (“artificial cells”): with emphasis on experiments in an extracorporeal shunt system. Trans Am Soc Artif Intern Organs. 1966;12:13–19.
25. Chang TM, Coffey JF, Barré P, et al. Microcapsule artificial kidney: treatment of patients with acute drug intoxication. Can Med Assoc J. 1973;108(4):429–433.,.
26. Chang TMS. Microencapsulated adsorbent hemoperfusion for uremia, intoxication and hepatic failure. Kidney Int. 1975;7:S387–S392.
27. Chang TMS, Endo Y, Nicolaev VG, et al., editors. Hemoperfusion and plasma-perfusion and other clinical uses of general, biospecific, immune and leucocyte adsorbents. Regenerative medicine, artificial cells and nanomedicine. Vol. 4. Singapore: World Scientific Publisher/Imperial College Press; 2017. p. 1004.
28. 10.1142/9789814749084_000110.1142/9789814749084_0001 ↗
29. 10.3109/10731199.2010.50492410.3109/10731199.2010.504924 ↗
30. 10.3109/21691401.2016.113849410.3109/21691401.2016.1138494 ↗
31. 10.1136/bcr-2019-22958210.1136/bcr-2019-229582 ↗
32. Arslan B, Kucukbingoz C, Kutuk M, et al. Single-center experience with resin adsorption hemoperfusion combined with continuous veno-venous hemofiltration for septic shock patients. Med Sci. 2019;8(2):390–394.
33. 10.3389/fmed.2020.60784910.3389/fmed.2020.607849 ↗
34. 10.1016/j.ijid.2020.05.06510.1016/j.ijid.2020.05.065 ↗
35. 10.1186/s13613-017-0287-010.1186/s13613-017-0287-0 ↗
36. Wang Y-T, Fu J-J, Li X-L, et al. Effects of hemodialysis and hemoperfusion on inflammatory factors and nuclear transcription factors in peripheral blood cell of multiple organ dysfunction syndrome. Eur Rev Med Pharm Sci. 2016;20:745–750.
37. 10.1111/j.1744-9987.2012.01083.x10.1111/j.1744-9987.2012.01083.x ↗
38. 10.1016/j.jgar.2020.04.02410.1016/j.jgar.2020.04.024 ↗
39. Liang Y, et al. Extracorporeal blood purification therapy using hemoadsorption type hemoperfusion improves ICU outcomes in critically ill patients with SAR-CoV-2 infection – a prospective cohort study. Lancet. 2020.
40. 10.1016/j.niox.2020.06.00210.1016/j.niox.2020.06.002 ↗
41. 10.1080/10715762.2021.193802410.1080/10715762.2021.1938024 ↗
42. 10.1080/08916934.2021.191358110.1080/08916934.2021.1913581 ↗
43. 10.1097/00005373-200112000-0002010.1097/00005373-200112000-00020 ↗
44. 10.1088/0967-3334/31/9/01310.1088/0967-3334/31/9/013 ↗
45. Red Cross declares first-ever blood crisis amid omicron surge. https://www.redcross.org/about-us/news-and-events/press-release/2022/blood-donors-needed-now-as-omicron-intensifies.html.
46. Bian Y, Chang TMS. A novel nanobiotherapeutical poly-[hemoglobin- superoxide dismutase-catalase-carbonic anhydrase] with no cardiac toxicity for the resuscitation of a 90 minutes sustained severe hemorrhagic shock rat model with 2/3 blood volume loss artificial cells. Nanomedicine and Biotechnology. 2015;43(1):1–9.
47. 10.1080/21691401.2018.147637510.1080/21691401.2018.1476375 ↗
48. 10.1080/21691401.2017.129367610.1080/21691401.2017.1293676 ↗
49. 10.1016/S0006-291X(71)80260-710.1016/S0006-291X(71)80260-7 ↗
50. Jahr JS. Hemoglobin-glutamer 250 (bovine) [HBOC-201, Hemopure®] clinical use in South Africa and comprehensive review of cardiac outcomes and risk/benefit in Peer-Reviewed, indexed studies in humans and animal models. In: Chang TMS, Bulow L, Jahr JS, et al., editors. Nanobiotherapeutic based blood substitutes. Singapore: World Science Publisher; 2021.
51. 10.1016/j.jamcollsurg.2008.09.02310.1016/j.jamcollsurg.2008.09.023 ↗
52. 10.1038/nbt0798-66710.1038/nbt0798-667 ↗
53. 10.1081/BIO-12000272510.1081/BIO-120002725 ↗
54. 10.3109/1073119970911890910.3109/10731199709118909 ↗
55. 10.1142/9789814472869_000810.1142/9789814472869_0008 ↗
56. 10.3109/1073119970911891010.3109/10731199709118910 ↗
57. Zal F. 2017. Use of HEMO2life – an innovative oxygen carrier in organ transplantation abstract. 2017 International Symposium on Blood Substitutes. www.artcell.mcgill.ca
58. 10.1142/9789814472869_000710.1142/9789814472869_0007 ↗
59. Kettisen K, Bülow L. Cysteine mutations in recombinant fetal hemoglobin influence oxidative side-reactions. In: Chang TMS, Bulow L, Jahr JS, et al., editors. Nanobiotherapeutic based blood substitutes. Singapore: World Science Publisher; 2021.
60. Chan G, Chang TMS. Dual effects include antioxidant and pro- oxidation of ascorbic acid on the redox properties of bovine hemoglobin. In: Chang TMS, Bulow L, Jahr JS, et al., editors. Nanobiotherapeutic based blood substitutes. Singapore: World Science Publisher; 2021.
61. Liu JX, Yang CM. Development and future of Chinese transfusion medicine and blood substitutes. In: Chang TMS, Bulow L, Jahr JS, et al., editors. Nanobiotherapeutic based blood substitutes. Singapore: World Science Publisher; 2021. p. 161–168.
62. 10.3109/21691401.2015.103547910.3109/21691401.2015.1035479 ↗
63. Chang TMS, BulowL, JahrJS, et al., editors. Nanobiotherapeutic based blood substitutes. Singapore: World Science Publisher; 2021. p. 1140.
64. Chang TMS. 2022. Artificial cells blood substitutes and nanomedicine website containing reviews and monographs for free online viewing or download www.artcell.mcgill.ca.
65. 10.3109/21691401.2015.111087110.3109/21691401.2015.1110871 ↗